ICT-107 is the company’s dendritic cell based cancer vaccine candidate that targets multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).
ImmunoCellular’s double-blind, placebo-controlled, 2:1 randomized Phase 2 trial is intended to investigate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM.
ImmunoCellular president and CEO Manish Singh said they look forward to generating data in support of the safety and efficacy of ICT-107 in the treatment of GBM and to further support the promising outcomes reported in our Phase I study.